Neumora Therapeutics (NMRA) Earnings Date, Estimates & Call Transcripts $9.74 +0.05 (+0.52%) (As of 11/22/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Neumora Therapeutics Latest Earnings SummaryUpcoming Q4 Earnings DateMar. 6EstimatedActual EPS (Nov. 12) -$0.45 Missed By -$0.06 Consensus EPS (Nov. 12) -$0.39 Neumora Therapeutics posted Q3 2024 earnings on November 12, 2024, reporting an EPS of -$0.45, which missed analysts' consensus estimates of -$0.39 by $0.06. With a trailing EPS of -$1.87, Neumora Therapeutics' earnings are expected to grow next year, from ($1.61) to ($1.60) per share. Conference Call TranscriptConference Call AudioNMRA Upcoming EarningsNeumora Therapeutics' next earnings date is estimated for Thursday, March 6, 2025, based off prior year's reporting schedules. Get Neumora Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neumora Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataNMRA Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.NMRA Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Chaikin Analytics50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could spell disaster for some of America's favorite tech companies. You can watch for it for free, right here. Neumora Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241-$1.56-$1.56-$1.56Q2 20241-$1.59-$1.59-$1.59Q3 20242-$0.38-$0.33-$0.36Q4 20242-$0.46-$0.46-$0.46FY 20246-$3.99-$3.94-$3.97Q1 20251-$0.47-$0.47-$0.47Q2 20251-$0.48-$0.48-$0.48Q3 20251-$0.49-$0.49-$0.49Q4 20251-$0.50-$0.50-$0.50FY 20254($1.94)($1.94)($1.94) Neumora Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 3/6/2025(Estimated)------- 11/12/2024Q3 2024-$0.39-$0.45 -$0.06-$0.45-- 8/6/2024Q2 2024-$0.37-$0.37--$0.37-- 5/7/2024Q1 2024-$0.34-$0.34--$0.34-- 3/7/2024Q4 2023-$0.76-$0.71+$0.05-$0.71-- 11/1/2023Q3 2023-$0.35-$1.14 -$0.79-$1.14-- Neumora Therapeutics Earnings - Frequently Asked Questions When is Neumora Therapeutics's earnings date? Neumora Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 6th, 2025 based off last year's report dates. Learn more on NMRA's earnings history. Did Neumora Therapeutics beat their earnings estimates last quarter? In the previous quarter, Neumora Therapeutics (NASDAQ:NMRA) missed the analysts' consensus estimate of ($0.39) by $0.06 with a reported earnings per share (EPS) of ($0.45). Learn more on analysts' earnings estimate vs. NMRA's actual earnings. How can I listen to Neumora Therapeutics's earnings conference call? The conference call for Neumora Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Neumora Therapeutics's conference call transcript? The conference call transcript for Neumora Therapeutics's latest earnings report can be read online. Read Transcript How much profit does Neumora Therapeutics generate each year? Neumora Therapeutics (NASDAQ:NMRA) has a recorded net income of -$235.93 million. NMRA has generated -$1.87 earnings per share over the last four quarters. What is Neumora Therapeutics's EPS forecast for next year? Neumora Therapeutics's earnings are expected to grow from ($1.61) per share to ($1.60) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies Halozyme Therapeutics Earnings Krystal Biotech Earnings ADMA Biologics Earnings Arcellx Earnings CRISPR Therapeutics Earnings Immunovant Earnings ImmunityBio Earnings Denali Therapeutics Earnings Kymera Therapeutics Earnings Vericel Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report 50-year Wall Street legend: “Sell this tech stock NOW” (Ad)Something very strange is happening to U.S. stocks following President Trump's victory... And this could spell disaster for some of America's favorite tech companies. You can watch for it for free, right here. This page (NASDAQ:NMRA) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of ...WealthPress | SponsoredBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | SponsoredJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purpose...Priority Gold | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredLet’s be bluntLet me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wro...DTI | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredFed Declares War on AmericansFed Declares War on Americans Protect your wealth in the coming months… True Gold Republic | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
